Paul Tudor Jones’s Novartis NVS Stock Holding History

Paul Tudor Jones’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.06M	Sell	25,900 -58,100	-69%	-$8.71M	0.01%	1433
2026 Q1	$12.8M	Buy	84,000 +76,700	+1,051%	+$11.8M	0.02%	618
2025 Q4	$1.01M	Buy	+7,300	New	+$956K	﹤0.01%	2271

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Paul Tudor Jones's NVS Position: Q2 2026 in Review

Paul Tudor Jones sold out of Novartis (NVS) in Q2 2026, closing a stake of 63,250 shares — an estimated $9.48M sold.

Paul Tudor Jones first reported a position in NVS in Q1 2024 and held it in 4 quarters. The position peaked at $9.66M in Q1 2026. 1,615 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Paul Tudor Jones reported no remaining Novartis position as of Q2 2026 after selling out during the quarter.
Paul Tudor Jones sold 63,250 Novartis shares in Q2 2026, an estimated $9.48M.
Paul Tudor Jones first reported a position in Novartis in Q1 2024 and held it in 4 quarters.
Paul Tudor Jones's Novartis position peaked at $9.66M in Q1 2026.
1,615 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.